18 Apr 2024 • Among birisk patients with ACS who completed 9 to 12 months of DAPT after PCI, subsequent treatment with clopidogrel was superior to continuing DAPT with aspirin and clopidogrel in reducing clinically relevant bleeding.

• In recent research published in JAMA Cardiology, 7758 PCI-treated birisk (both high bleeding and ischemic risk) patients with ACS who completed 9 to 12 months of dual antiplatelet therapy (DAPT) after PCI, clopidogrel monotherapy for an additional 9 months resulted in a 25% reduction in the risk of Bleeding Academic Research Consortium types 2, 3, or 5 bleeding compared with clopidogrel plus aspirin.

Source: JAMA | Read full story